Comparing Nanobiotix (NASDAQ:NBTX) and Galectin Therapeutics (NASDAQ:GALT)

Nanobiotix (NASDAQ:NBTX) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.

Volatility & Risk

Nanobiotix has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

Institutional and Insider Ownership

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Nanobiotix and Galectin Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87 million	53.30	-$27.11 million	N/A	N/A
Galectin Therapeutics	N/A	N/A	-$30.84 million	($0.41)	-6.59

Nanobiotix has higher revenue and earnings than Galectin Therapeutics.

Profitability

This table compares Nanobiotix and Galectin Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Galectin Therapeutics	N/A	N/A	-164.69%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Nanobiotix and Galectin Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1	1	4	0	2.50
Galectin Therapeutics	1	0	1	0	2.00

Nanobiotix presently has a consensus target price of $26.67, suggesting a potential downside of 34.16%. Galectin Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 307.41%. Given Galectin Therapeutics’ higher probable upside, analysts clearly believe Galectin Therapeutics is more favorable than Nanobiotix.

Summary

Nanobiotix beats Galectin Therapeutics on 7 of the 9 factors compared between the two stocks.

About Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

About Galectin Therapeutics

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.